"How large is the opportunity and who controls access?"
An incidence-to-eligible funnel built as a live, re-runnable Excel model: 8 sheets, 119 formulas, zero hardcoded cells. Every conversion step sourced, every assumption editable.
Browse PFM →Coverage criteria and the evidence standard. How payers and HTA bodies evaluate access and step-edits.
Browse P&HTA →A 12-sheet pricing architecture built market by market: price ladder, international reference-price basket, value-based ICER, gross-to-net waterfall, launch sequencing, and revenue scenarios — not a single number, a re-runnable model.
Browse PSM →A static, triangulated patient-count model, not a forecast: 5-sheet workbook (Cover, Model, Research Validation, QC, Sensitivity), every input sourced and re-runnable. Sizing answers how many patients exist today; forecasting is a separate question.
Browse MSM →A 9-sheet HTA submission-strategy model: authority landscape, PICO framework, comparator defence, value-dossier self-assessment, HEOR gap register, and submission timeline — built before the dossier is written, not after.
Browse HTA →Incidence-to-eligible NSCLC funnel by cohort with sourced conversion assumptions and a share waterfall.
CMS routes all four approved 1L NSCLC IO agents through Part B buy-and-bill at ASP+6%, but PD-L1 assay requirements split coverage into three distinct biomarker-testing tiers.
Why the orphan-drug exclusion shields anti-C5 agents from IRA negotiation, ICER's 2024 value verdict on iptacopan, and Part B vs Part D routing.
Tafamidis is shielded from IRA negotiation by the orphan-drug exclusion — ICER judged its ~$268K price ~85–95% too high, and acoramidis plus pending generics are the real net-price levers.
Specialty-tier prior authorization, prophylaxis above $300K/patient/yr, ICER 2018/2021 value-based benchmarks and no-concurrent-acute-agent rules.
How US payers gate the five FDA-approved IgAN therapies — biopsy, proteinuria and RAS-blockade step-through, the Filspari REMS, Part D routing and the ICER 2026 assessment.
ICER priced efgartigimod's value at $18,300 to $28,400 a year, under half its ~$418,400 launch cost, and that gap is hardening into a three-tier FcRn-to-C5 step-edit across US commercial plans.
IV enzyme replacement buy-and-bill under Part B vs oral SRT under Part D, the CYP2D6 PA gate, and generic miglustat.
Zolgensma's $2.125M one-time cost, outcomes-based Medicaid contracts, and Part B vs Part D routing across three SMA modalities.
Gene-therapy access at $2.2–3.1M, the CMS Cell & Gene Therapy Access Model, VOC-freedom endpoints, and the hydroxyurea step-edit.
Fintepla's list price runs roughly 3x Epidiolex, and payer scrutiny turns on high WAC against a small, severe paediatric population.
A genetic test gates oral migalastat, IV enzyme replacement sits in Part B, and Fabrazyme has no US biosimilar — though the IRA's orphan-drug exclusion shields it from Medicare price negotiation.
Pompe ERT costs near $400,000 a year in Part B, Pombiliti + Opfolda splits into two simultaneous prior authorisations across Part B and Part D, and Pompe remains the only major rare-disease ERT category ICER has never reviewed.
Sutimlimab (Enjaymo) is a ~$260K+/year Part B IV biologic in a few-thousand-patient population — and not cost-effective at the current price.
Topical-then-biologic step-therapy, JAK black-box PA gates, ICER's dupilumab-aligned and JAK-discount verdicts, and why Dupixent is not IRA-selected.
Why Rezdiffra's $47,400 WAC lands inside ICER's value range, why the IRA reset hits semaglutide first, and how Part D routing shapes MASH access.
Type 2 Diabetes is IRA ground zero: three orals negotiated for 2026, semaglutide at $274 for 2027, and the class price anchor reset.
Why CMS's coverage-with-evidence-development registry, not IRA negotiation, is the anti-amyloid access gate, plus ICER's below-value verdict and Part B routing.
Why Medicare covers Wegovy only for cardiovascular risk, how the IRA's IPAY 2027 semaglutide price applies across the franchise, and ICER's 2025 'high value' verdict.
COPD access is a pharmacy-benefit story: inhalers and biologics run through Medicare Part D and commercial PBMs, not medical coverage. Step edits gate the base, an eosinophil threshold gates the biologic, and the IRA is reshaping both price exposure and negotiation risk.
US access to plaque psoriasis biologics is gated by step therapy and reshaped by two forces landing together: Inflation Reduction Act price negotiation on Stelara and Enbrel, and biosimilar erosion of adalimumab and ustekinumab.
US access to HR+/HER2- oral therapies runs through Medicare Part D and commercial prior authorization, and the price ceiling is now being set directly by the government: palbociclib was selected for Medicare negotiation with a 50% cut ($15,741 to $7,871) effective 2027. Newer targeted agents face biomarker-gated coverage and cost-effectiveness ratios far above accepted thresholds.
US gMG prevalence runs 100,000-200,000, but only 4,000-6,000 patients are on FcRn therapy today, and 1,200-2,100 of those remain inadequately controlled — the near-term opportunity is the funnel gap, not the epidemiology total.
Three NICE technology appraisals (TA606, TA738, TA1101) each carry a confidential Patient Access Scheme, so garadacimab's published £20,625 per-pen price is the only fully transparent figure in the class, and two MHRA-licensed agents still have no NICE-confirmed net price.
NPHC's KSA-first coverage model sets the de facto GCC access bar for anti-C5 agents — iptacopan faces a 12-24 month SFDA registration queue before NPHC even evaluates it.
Carrier-rate-adjusted epidemiology implies 140,000-200,000 KSA patients, but NPHC's structured active-management programme reaches only 8,000-10,000, a care-registration gap, not a measurement error.
The UK Pompe Consortium registry counts roughly 200 confirmed patients. Total estimated prevalence, including the undiagnosed pool, runs 350-450. Within the confirmed, treated population, 30-50 are ADA-positive inadequate responders and 80-120 are on home ventilation.
Why the GCC's largest rare-disease programme by patient volume (8,000-10,000 NPHC-managed SCD patients) sits in a commercial vacuum, with crizanlizumab and voxelotor both withdrawn, ahead of 2025-26 gene therapy registration.
NPHC's negotiated Zolgensma price runs $1.5-1.8M against $2.125M US list, but the real mechanism is a 24-month motor-milestone rebate, the same structure now anchoring risdiplam and nusinersen pricing across the Gulf.
Lanadelumab tenders at SAR 300,000-400,000 a year, but NPHC has no routine formulary price at all; access runs through an individual-case bar only 30-40% of submissions clear, while private VHI approves at a materially lower documentation threshold.
Total GCC Pompe prevalence runs 400-600, consanguinity-elevated. 200-300 are actively managed on ERT, and NPHC's formulary budget centers on a narrower 80-120 long-term-stable core within that population.
US SMA sizing splits into two live populations, not one number: 8,000-10,000 prevalent patients across Types 1-4, and a separate 500-700-patient Zolgensma-treated cohort now aging into a monitoring window where 15-20% show early motor plateau.
An estimated 8,000-9,000 Americans have HAE; only 35-40% receive any prophylaxis, leaving 2,500-4,000 attack-eligible patients never treated, a pool nearly as large as the entire treated population.
A 37-centre national survey confirms 1,152 UK HAE type I/II patients, a top-down 1:32,000 prevalence rate implies roughly 2,000, and the UK HAE Alliance's broader planning estimate runs to 5,000-6,000, of which only 1,500-2,000 are on prophylaxis today.
The UK SMA population is not one number. A ~1,000-patient actively-monitored NHS cohort and a 1,800-2,000-patient total prevalence estimate both appear across UK sources, and the gap between them is the pre-NBS legacy population outside the four specialist networks' active census.
GCC SMA incidence runs 1:6,000-8,000 against a global 1:10,000, and newborn-screening coverage splitting 90%/85%/75% across KSA/UAE/Qatar means the addressable near-term population depends on which country's screening curve a launch model assumes.
NICE's rejection-then-reversal of Zolgensma (2021→2023) established a Long-Term Value Framework precedent that now makes one-time gene therapy the NHS's preferred economic choice for newborn-screened SMA infants.
Epidemiology implies 1,200-1,500 true GCC HAE patients; the KFSH&RC registry confirms fewer than 200; and a separate planning estimate used for launch work lands at 400-600 — three numbers, one diagnostic-capacity story.
100,000-200,000 US gMG patients narrow to a 4,000-6,000 on-FcRn-therapy pool, and 1,200-2,100 of them remain inadequately controlled despite treatment.
12,000-15,000 UK gMG patients on the broader estimate, of whom ~4,000 have moderate-severe disease and 2,000-3,000 are refractory, with no NICE-recommended novel agent for any of them.
Both ravulizumab and iptacopan cleared NICE's standard Technology Appraisal route (TA698 and TA1000) at the ordinary £20,000–£30,000/QALY bar — the real payer question is how fast NHS converts patients from IV ravulizumab to oral iptacopan, not which drug got the easier appraisal.
Why NICE recommended both Dravet therapies through standard Technology Appraisal rather than the ultra-rare HSS route, what the Fintepla Cardiac Monitoring Scheme costs the NHS, and why the UK treatment algorithm is now closed to new entrants without a significant clinical edge.
An estimated 100,000 US sickle cell disease patients narrow to a 55,000-65,000-patient pool with no adequate novel therapy, while only 50-100 of the gene-therapy-eligible minority were actually treated in year one.
5,000-10,000 diagnosed US classic Fabry patients, a 35-50% amenable-mutation gate to oral therapy, and a treated population still 60-65% on enzyme replacement. This funnel starts at diagnosis because no defensible undiagnosed estimate exists yet.
6,000-10,000 GCC gMG patients on the epidemiology estimate, of whom 200-300 are refractory and fewer than 50 are currently on biologic therapy.
15,000-17,000 diagnosed UK sickle cell disease patients, universal since 1999 newborn screening, narrow to a 4,000-6,000-patient conventional-therapy gap and a separate 200-300-per-year gene-therapy-eligible pool.
Why GCC tafamidis costs roughly a tenth of its US price yet uptake is limited not by affordability but by Tc-PYP scintigraphy access at fewer than 8 GCC centres.
700-900 NHS-diagnosed Fabry patients split cleanly: roughly 600 on enzyme replacement, about 200 (25%) on oral migalastat, and free NHS cascade testing that adds 3-4 diagnosed relatives per index case.
6,000-8,000 US Dravet patients, roughly three-quarters SCN1A-confirmed, and 35-40% still inadequately controlled on cannabidiol plus fenfluramine, the population any new agent must actually reach.
Iptacopan's substantial-benefit finding gave Germany real negotiating leverage over Novartis. Six months on, no negotiated net price has surfaced in the Lauer-Taxe — the pricing signal this model is built to catch before a launch-sequencing decision locks in the wrong assumption.
8,000-10,000 US SMA patients, a Type 1-4 severity split running roughly 60/27/13/under 5 percent, and the 500-700-patient Zolgensma cohort this funnel validates against.
NHS England's Pompe commissioning-policy continuation criteria define a 45-50 patient switch-eligible cohort for avalglucosidase alfa (NICE TA821) — a manageable NHS budget event, while broader first-line uptake would be a materially larger one.
GCC male Fabry prevalence runs 1:20,000-30,000, elevated by founder mutations, yet only 200-300 patients are diagnosed against a true burden estimated 3-5 times higher, and female diagnosis lags under half the male rate.
NICE accepts palbociclib, ribociclib, and abemaciclib as comparators for each other. No trial has ever tested any of them head-to-head against exemestane plus everolimus, the older endocrine-based comparator regimen they effectively replaced.
NICE has cleared every modern PNH anti-complement therapy, from ravulizumab to crovalimab, through the standard £20,000-30,000 Technology Appraisal route rather than the more generous Highly Specialised Technologies threshold, each via a confidential patient access scheme.
500,000+ US patients aged 70+ with HFpEF carry undiagnosed ATTRwt-CM, against only 70,000-100,000 diagnosed and treated. Two further sub-populations, Val122Ile carriers and ATTR-PN, remain even less visible.
2,000-2,500 UK Dravet patients, of whom 400-500 are SCN1A-molecularly-confirmed in genetic registries, and 600-900 still inadequately controlled on cannabidiol plus fenfluramine.
An estimated 8,000-9,000 Americans live with hereditary angioedema. Just 35-40% receive any prophylaxis, leaving 2,500-4,000 patients who meet treatment criteria untreated, the funnel this model sizes precisely.
True UK ATTRwt-CM prevalence runs 20,000-40,000, and 15,000-36,000 of those patients remain undiagnosed. Only 3,000-4,000 are on NHS-commissioned tafamidis today, adding 1,500-2,000 a year.
A ~1,000-patient confirmed UK SMA cohort by type, reconciled against a 1,800-2,000-patient total prevalence estimate, and a 50-60/yr Zolgensma cohort as the on-therapy validation anchor.
Agalsidase beta was never formally appraised by NICE, while migalastat's HST4 recommendation (2016) was the first oral mutation-specific rare disease therapy NICE approved; together they underpin an estimated £144M NHS Fabry programme, with a £70-130K/patient/year switch incentive still unrealised at scale.
600-800 estimated GCC Dravet patients, fewer than 200 SCN1A-molecularly-confirmed, and a 200-400 near-term addressable cohort within that confirmed subset.
The UK HAE Alliance counts 5,000-6,000 total patients, of whom 1,500-2,000 are on NICE-commissioned prophylaxis. A further 1,500-2,500 are attack-active but never treated, and Longhurst et al.'s 37-centre registry confirms 1,152 patients from the bottom up.
15,000-20,000 Americans carry a PNH clone, but only about 3,500 reach complement-inhibitor therapy, and up to 1,200 of them stay anemic on it. This model sizes every gap in between.
GCC SMA incidence of 1:6,000-8,000 births, country-level newborn-screening coverage from 90% down to under 50%, an 800-1,200-patient legacy Type 2/3 pool, and a 60-80/yr Zolgensma cohort as the on-therapy anchor.
Epidemiology projects 1,200-1,500 GCC HAE patients; the GCC allergy society's own case registry counts only 400-600. The gap is not a contradiction, it is the diagnostic-capacity constraint of just 6-10 specialist physicians across all six states.
Two GCC ATTR-CM burden estimates, 15,000-25,000 and a narrower 2,000-5,000 ATTRwt-CM cohort, both convert to fewer than 1,000 confirmed diagnoses. This model reconciles the gap and traces it to scintigraphy access.
~600-750 UK PNH patients are on active complement-inhibitor therapy against a reconciled total prevalence near 1,500; the other 750-900 are monitored-only or undiagnosed, and this model sizes the gap.
5,000-10,000 Americans live with Pompe disease. Roughly 2,000 late-onset patients are on enzyme replacement therapy, and 375-600 of them, one in four, are inadequate responders, the subtype this model is built to size.
France's PMSI hospital database counts 897 PNH patients over five years; Orphanet's older estimate puts national prevalence at 850-1,000. Only 270 of them, per the manufacturer's own estimate, are eligible for a second-line oral agent.
350-450 UK Pompe disease patients, of whom roughly 200 form the registry-confirmed cohort. One in four long-term ERT patients is not holding stable, the segment this model is built to size.
The UK's NICE-commissioned Dravet treatment algorithm manages an estimated 2,000-2,500 patients on cannabidiol and fenfluramine, but the NHS genetic testing registry logs only 400-500 molecularly SCN1A-confirmed cases — a registry-scope gap, not a population contradiction.
400-600 GCC Pompe disease patients, of whom 200-300 are on enzyme replacement therapy. Just 40-60, patients with FVC decline despite alglucosidase already on home ventilation, are the segment this model is built to size.
GCC Dravet prevalence is estimated at 600-800 patients from epidemiology, but fewer than 200 are molecularly SCN1A-confirmed, and the 200-400 figure used in launch planning is a distinct near-term actionable tier, not a fourth competing total.
GCC ATTR-CM burden runs 15,000-25,000 by broad HFpEF-adjacent estimate, or 2,000-5,000 by the narrower near-term-addressable ATTRwt-CM cohort, and fewer than 8 centres with scintigraphy capacity explain why so few of either total converts to a confirmed diagnosis.
NICE's SCD gene therapy appraisal, potentially the largest NHS rare disease budget event in history, hinges on an annuity payment model that current NHS SCD management cost cannot yet clearly justify.
NICE's accepted cost-effectiveness case for budesonide (TA937, updated by TA1128) rests on a 5–8 year modelled ESRD delay, and the same mandatory ACEi/ARB gate applied to sparsentan narrows the UK's eligible IgA nephropathy population from 10,000–15,000 to 3,000–5,000 patients.
Why the most effective Dravet agent is the least accessible in the GCC — cannabidiol's Schedule-1-equivalent narcotics classification caps exceptional-import approval at 35-40%.
NICE has never modelled a cost-per-QALY for a myasthenia gravis biologic. Eculizumab's appraisal (TA636) closed before a dossier was submitted; efgartigimod's (TA1069) closed on evidence gaps, not a quantified ICER breach. A new entrant inherits no reusable comparator or price benchmark from either.
NICE accepts a £100,000-300,000 QALY threshold for ultra-rare Pompe disease under its Highly Specialised Technologies pathway, five to fifteen times the £20,000-30,000 bar a standard technology appraisal applies. Avalglucosidase alfa's TA821 recommendation used that ceiling, but only with a substantial confidential commercial arrangement. A new entrant without that leverage should build a standalone case for the antibody-positive inadequate-responder subgroup instead.
Why SMA is the most mature rare-disease access model in the GCC — all three modalities NPHC-covered, with Zolgensma's outcomes-based milestone rebate as the GCC-first template other programmes are built to follow.
Both existing Dravet therapies cleared NICE's standard Technology Appraisal, not the ultra-rare Highly Specialised Technology route. A new entrant's WAC, PAS, and stakeholder-engagement calendar all need to be built against that lower cost-effectiveness bar, with soticlestat's 2026-27 appraisal setting the clock.
200,000-250,000 GCC-wide sickle cell disease patients (140,000-200,000 in Saudi Arabia alone), but NPHC's actively-managed registry reaches only 8,000-10,000 — the addressable near-term funnel stage within a much larger under-managed population, not a contradiction.
NICE's June 2025 rejection of efgartigimod (TA1069) leaves UK myasthenia gravis with no NICE-recommended novel agent — eculizumab's own appraisal (TA636) was withdrawn by the manufacturer in 2020 without a cost-effectiveness verdict, and the NHS IVIg cost-offset argument is now the strongest lever for a future resubmission.
Why IgA nephropathy has no NPHC programme at all — access runs entirely through hospital pharmacy committees or private insurance, gated by a biopsy available at fewer than 20 GCC centres.
NICE TA606 commissioned lanadelumab with PAS and 87.5% real-world attack reduction — berotralstat's NICE TA738 recommendation is now tested against that same benchmark.
Why NPHC has a 72%-cost-reduction financial incentive to switch amenable-mutation Fabry patients from ERT to migalastat — and why a single HEK293 assay lab in the entire GCC is the only thing standing in the way.
Why NPHC's well-established Pompe programme still gates avalglucosidase behind a 12-month failed-response switch criterion — and why Sanofi is pursuing NPHC first-line approval to bypass it.
Fabrazyme's orphan-drug exclusion under the IRA shields it from Medicare price negotiation entirely, and no rebate or net-price figure is disclosed anywhere in the primary record for any Fabry therapy. The orphan exclusion, not a discount ladder, is what a Fabry pricing strategy has to be built around.
Two UK gMG estimates disagree by 3-4x on purpose: a narrower moderate-severe subgroup of roughly 4,000 (MGA UK survey) sits inside a broader 12,000-15,000 total prevalence figure that also counts mild, well-controlled cases the narrower estimate excludes.
GCC gMG sizing treats the 6,000-10,000-patient disease-landscape prevalence estimate as the authoritative broad base, with a 200-300-patient refractory subgroup, fewer than 50 currently on a biologic, as the narrower actionable segment inside it, not a competing total.
316,950 annual US invasive breast cancer diagnoses and a 6.0% metastatic-at-diagnosis rate size the incident flow. Layering CDK4/6-inhibitor and post-progression pricing onto that flow, and onto the separate, larger recurrence pool, is what turns a patient count into a market value.
Wegovy lists at roughly $1,349 a month, but CMS pays $274 for a 30-day semaglutide supply starting 2027, a 71% cut that applies to Ozempic, Rybelsus, and Wegovy alike. Tirzepatide sits outside the negotiation entirely, for now.
6.7 million Americans have F2-F3 MASH, but Rezdiffra has already reported 42,250+ patients on therapy and $311.3M in Q1 2026 revenue. This model triangulates population against real uptake, not a modeled guess.
Two IRA negotiation cycles have now cut across the T2D formulary: Januvia down 79% to $113, Jardiance down 66% to $197, Farxiga down 68% to $178 from January 2026, and semaglutide down 71% to $274 with Janumet and Tradjenta added for 2027.
IQVIA puts the 2023 US T2D drug market at $22B top-down. Triangulated bottom-up against 29.7M diagnosed patients out of 38.4M with the disease, the two methods converge, but per-class revenue split remains an open gap this model flags rather than invents.
Stelara's negotiated price falls to $4,695 from a $13,836 list, a 66% cut, effective January 2026, the same month ustekinumab biosimilars begin launching. Two separate pricing shocks land on one legacy biologic at once.
Three IV enzyme replacement brands run ~$300,000/year with no generic rival, so preferred-ERT designation is the real pricing lever. Eliglustat's CYP2D6 gate and generic miglustat's trial-first rule complete the picture.
A GCC nephrology network capacity survey estimates 8,000-12,000 IgA nephropathy patients across the region, but the same survey finds kidney biopsy performed in fewer than 30% of eligible proteinuric patients, and zero patients are on any SFDA-registered novel agent as of 2024.
Iptacopan's ~$550,000 annual WAC sits roughly 71% above ICER's own $156,000-157,000 value-based benchmark, yet the orphan-drug exclusion keeps anti-C5 incumbents priced outside IRA's reach entirely, the two forces any new US PNH entrant must price against.
The Leeds National PNH Registry tracks about 600 UK patients on complement-inhibitor therapy, but AXLRx's own Launch Readiness research cites a broader estimate near 1,500 total patients and 1,000 treated. Reconciling which count anchors a sizing model is the open question.
Germany's DGHO Onkopedia guideline states plainly that Germany-specific PNH prevalence and incidence figures do not exist. It borrows 16 cases and 1.3 new diagnoses per million annually from British and French registries, and routes all case-finding through just two national centres, Ulm and Essen.
An estimated 2,000-3,000 Gulf patients carry a clinically significant PNH clone, but only about 400 are confirmed in national registries, and just 150-250 reach complement-inhibitor therapy. Diagnostic capacity, not drug access, is the constraint this model sizes.
Germany has no domestic PNH prevalence count of its own; DGHO's Onkopedia guideline borrows a 16-per-million estimate from British and French registries. Only two national centres, Ulm and Essen, anchor referral.
An estimated 8,000-12,000 GCC IgAN patients narrow to fewer than 30% ever biopsied, then to zero on novel therapy, since no agent is SFDA-registered as of 2024. The funnel gap, not the prevalence estimate, is what a GCC patient flow model has to size.
NICE built UK SMA access in sequence: gene therapy took the pre-symptomatic subgroup first (HST15, HST24), then TA1162 moved chronic therapy to routine funding behind it. A new entrant inherits a fixed subgroup hierarchy and a comparator that shifts by population, not an open field.
NICE recommends both ATTR-CM stabilisers, tafamidis (TA984) and acoramidis (TA1121), and directs clinicians to the cheaper one. Acoramidis cleared on indirect comparison alone. A third entrant must beat an invisible, PAS-discounted floor, with no published price target.
Three completed NICE standard technology appraisals already fund HAE prophylaxis in England (TA606, TA738, TA1101), every one cleared at the ordinary £20,000 to £30,000 per QALY bar and held behind a confidential Patient Access Scheme, so a new entrant inherits a comparator-dense field in which garadacimab's £20,625 list pen is the only transparent price.
UK Fabry disease is commissioned through three different NICE and NHS routes at once: no formal NICE technology appraisal for either enzyme replacement therapy, a Highly Specialised Technologies recommendation (HST4, 2016) for migalastat, and a standard technology appraisal (TA915, 2023) for pegunigalsidase alfa. A new entrant inherits no single reusable comparator or price benchmark.
150,000 US IgA nephropathy patients, of whom 70,000-90,000 are biopsy-confirmed. Only 5,000-8,000 are on novel therapy today, while 15,000-25,000 patients with UPCR above 1g/g remain the addressable high-risk cohort this model sizes precisely.
10,000-15,000 UK IgA nephropathy patients, of whom approximately 8,000 are tracked in the UK Renal Registry. Only 3,000-5,000 clear the mandatory ACEi/ARB and SGLT2i optimisation gate to become eligible for a novel agent, and fewer than 500 currently access one pre-NICE.
All five FDA-approved IgAN therapies clear the same prior-authorization gate, biopsy-confirmed diagnosis, UPCR 0.8-1.5 g/g, eGFR 30 or higher, RAS-blockade step-through, rather than a negotiated rebate table. No formal net-price data exists because access here runs on step-therapy criteria, not payer negotiation.
NICE accepted an eGFR-slope-to-ESRD-delay model, not the headline proteinuria reduction, as the value basis for budesonide (TA937, expanded by TA1128) and sparsentan (TA1074) in IgA nephropathy. The mandatory ACEi/ARB and SGLT2 inhibitor optimisation gate narrows the UK's 10,000 to 15,000 patients to a 3,000 to 5,000 novel-agent-eligible pool before that pricing math applies.
GCC HAE access is structurally two-tier — broad acute coverage, but an NPHC individual-case prophylaxis bar only 30-40% of applicants clear, and private insurance beats the NPHC pathway on speed.
Why generalised myasthenia gravis has no formal NPHC programme — efgartigimod access runs through private insurance (fastest, 1-4 weeks) or hospital pharmacy committees, with NPHC engagement targeted for 2025-2026.
Sutimlimab costs $259,000-$302,000 per patient per year, and a peer-reviewed analysis puts its ICER at $2.34M/QALY, standard of care favored in all 10,000 probabilistic-sensitivity iterations. The value gap, not a rival drug, sets the pricing discipline.
US cold agglutinin disease sizing starts from a rate range, not a point estimate: incidence 0.6-1.2 and 1-year prevalence 1.4-3.1 per 100,000, implying ~5,000 prevalent patients. No published treated-share figure exists to split served from total addressable.
The MedlinePlus-sourced count of 6,000 US Type 1 Gaucher patients sizes a market near $1.8 billion at ERT pricing, and the same population sits inside a genetic sub-segment where Ashkenazi carrier frequency runs 1 in 12-15 against a general-population disease frequency of just 0.70-1.75 per 100,000.
NICE has cleared four modern PNH anti-complement therapies (ravulizumab TA698, pegcetacoplan TA778, iptacopan TA1000 and crovalimab TA1019) through its standard £20,000-30,000 Technology Appraisal route, each contingent on a confidential commercial arrangement, never the Highly Specialised Technologies threshold. A new submission inherits an unbroken standard-STA precedent it must be built to clear from the first dossier decision.
NICE recommended crizanlizumab (TA743) via managed access in 2021, then withdrew it in 2023 after the confirmatory trial failed; Casgevy (TA1044) cleared only by restructuring its £1.65M price into managed access. A new entrant inherits no reusable ICER benchmark from either.
IgA nephropathy sits outside NPHC's genetic/orphan disease scope entirely, so there is no GCC formulary price to model. Budesonide clears case-by-case at SAR 80,000-120,000/year through hospital committees or private insurance; sparsentan is not yet tender-priced at all.
Iptacopan's orphan-drug status let it clear Germany's AMNOG process with an established additional benefit and no comparator dossier at all. Ravulizumab's only PNH-specific G-BA review found no added benefit.
HAS splits PNH into two tracks: ravulizumab holds SMR important and first-line, priced at €14,988.66 per 1100mg vial. Iptacopan cleared only ASMR III, restricted to second-line, its €29,590.96 box price negotiated against a manufacturer-declared population of 270 patients.
US PNH prevalence spans 15,000 to 20,000 patients across three phenotypes, but only about 3,500 are on complement-inhibitor therapy. A 2.4-year average diagnostic delay, plus 200 to 400 patients a year undertreated at non-PNH centres, accounts for most of that gap.
NICE's accepted 20-35% PAS discount off budesonide's WAC sets the pricing floor sparsentan already clears too, against a £140-180M NHS budget ceiling once the ACEi/ARB gate narrows eligibility to 3,000-5,000 patients.
Fintepla's weight-based list price runs roughly 3x Epidiolex, and payers work that gap through step-edit design layered on Part D pharmacy-benefit routing. No generic cannabidiol reaches the US market before the late 2030s.
France's PMSI national hospitalization database identified 897 PNH patients between 2018 and 2022, putting 2022 prevalence near 1 in 94,000, below the 1-in-70,000-to-80,000 range Orphanet and France's national rare disease plan have long cited.
Agalsidase beta runs an estimated £150-250K per patient per year against migalastat's £80-120K, a £70-130K annual switch saving NICE has already quantified but the NHS has not captured at scale, with pegunigalsidase's TA915 commercial arrangement now setting a third price point.
An estimated 150,000 Americans have IgA nephropathy, but only 70,000-90,000 are biopsy-confirmed and just 5,000-8,000 are on a disease-specific therapy today, within a 15,000-25,000-patient high-risk eligible cohort.
Both NHS-commissioned Dravet therapies cleared NICE's standard £20,000-30,000/QALY bar, not the ultra-rare HSS threshold, so a new entrant is held to the same cost-effectiveness bar the incumbents already cleared. Total NHS Dravet spend still runs a modest £9-16M.
The UK Renal Registry actively tracks about 8,000 IgA nephropathy patients against an estimated 10,000-15,000 total prevalence; only 3,000-5,000 are eligible for a novel agent, and fewer than 500 currently receive one.
NPHC pays roughly SAR 1.2-2.4M per patient per year for enzyme replacement against SAR 400-600K for migalastat, a 72% differential that gives NPHC a direct financial incentive to switch eligible patients, capped almost entirely by a single-laboratory diagnostic bottleneck rather than by price.
GCC Dravet pricing is an import-cost economics problem, not a rebate negotiation: cannabidiol's Schedule-1-equivalent narcotics classification adds USD 10-15K in compassionate-programme cost plus SAR 5-8K in import logistics, while stiripentol's non-narcotic status keeps it at SAR 30-50K through standard hospital import.
Roughly 5,000-10,000 diagnosed US Fabry patients split first by GLA amenability (35-50% oral-eligible) and then by ADA status, narrowing to a precise 200-400 patient addressable niche that a Fabrazyme-anchored $250-350K WAC makes commercially calculable.
Tafamidis prices 12-17x above ICER's fair-value benchmark, yet the orphan-drug exclusion keeps it out of IRA negotiation. Acoramidis and pending generics, not Medicare, now set net price.
Casgevy and Lyfgenia list at $2.2M and $3.1M, but CMS's Cell and Gene Therapy Access Model, Medicaid concentration, and a $1.5-1.9M ICER ceiling decide the realized net, not the sticker price.
US Dravet syndrome incidence of 1 in 15,700 births is consistent with the Dravet Syndrome Foundation's 6,000-8,000 prevalence estimate, but only 35-40% of that population, 1,400-2,000 patients, remains inadequately controlled on today's two branded agents.
Saudi Arabia's rare disease registry counts about 400 confirmed PNH cases. Global prevalence rates, adjusted for the region's 25-50% consanguinity rate, imply a true GCC PNH population 20-30% higher, and fewer than 15 labs across six countries can even run the diagnostic test.
700-900 diagnosed UK Fabry patients split roughly 600 ERT to 200 oral, inside which two further niches sit: 50-80 ADA-positive suboptimal responders and 80-120 undertreated symptomatic female heterozygotes, against a £144M NHS spend anchor.
NICE's TA1121 cost-minimisation rule directs clinicians to whichever ATTR-CM stabiliser costs less. That rule, not the QALY threshold alone, now sets a new entrant's UK price ceiling.
GCC anti-C5 tender pricing already runs 40-60% of US WAC, anchored to whichever EU comparator prices lowest, then compounded with a further 10-20% negotiation discount. Iptacopan has to clear the same cascade, still 12-24 months from SFDA registration.
NICE rejected crizanlizumab at £733K-1.1M per QALY even with a PAS discount. Casgevy cleared only via a 10-year annuity at £165K/year, and any new non-gene agent must land near £15-25K/year to clear that same ceiling.
Pompe ERT WAC runs near $400,000 a year, and the Pombiliti + Opfolda regimen splits across Medicare Part B and Part D. Zero ICER reviews exist today, with one expected in 2025 and a 12-month J-code lead time for any new entrant.
200-300 diagnosed GCC Fabry patients against a true prevalence estimated 3-5 times higher, undercounted because a single regional laboratory gates the amenable-mutation test and female heterozygotes are diagnosed at under half the male rate.
ICER priced efgartigimod's value at $18,300-28,400 a year, under half its ~$418,400 assumed launch price, and that gap is hardening into a three-tier step-edit staircase across US commercial and Part B plans.
Ibrance's Medicare-negotiated price takes effect a full year before Kisqali's and Verzenio's. Three clinically equivalent drugs, staggered IRA negotiation cycles, means Pfizer sets the reference point Novartis and Lilly then have to negotiate against.
HAS rated iptacopan ASMR III but restricted it to second-line use, while ravulizumab holds SMR important and first-line status. CEPS negotiated iptacopan's price against a manufacturer-estimated population of just 270 patients.
GCC tafamidis pricing is not one number. Private-import pricing near SAR 820,000-850,000/year describes the pre-registration state; post-registration tender pricing near SAR 70,000-90,000 describes what follows.
316,950 new US invasive breast cancer diagnoses in 2025. Only 6.0% present as metastatic at diagnosis, but 73.9% of the metastatic population is HR+/HER2-, the subtype this model is actually built to size.
NHS-commissioned alglucosidase alfa runs £200,000-350,000 per patient a year post-PAS. Avalglucosidase alfa's NICE TA821 recommendation carries a 20-30% WAC premium and a switch-population budget impact of just £2-4M a year.
At 200,000-250,000 GCC patients, US or UK list pricing is commercially impossible. NPHC's own exceptional-access threshold caps a novel agent near SAR 8,000-20,000/year, a fraction of a $2.2M gene-therapy WAC.
No UK gMG biologic has ever cleared NICE at any price. Eculizumab's manufacturer withdrew before submitting an ICER, and efgartigimod's June 2025 rejection means a future entrant's price ladder starts from zero precedent, not a benchmark.
A ~100,000-patient US population narrows to a 55,000-65,000-patient addressable white space, but only 50-100 gene-therapy patients were actually treated in the first 12 months versus 200-300 projected.
NICE TA696 (May 2021, since updated by TA984) opened NHS commissioning of tafamidis for ATTR-CM at scale — acoramidis’s pending appraisal and vutrisiran’s TA868 access route are the two other decisions defining the UK amyloidosis market.
Zolgensma's $2.125M sticker price obscures the real US SMA pricing lever: a 10-state Medicaid outcomes-based annuity paying $212,500 a year for ten years, set against chronic Spinraza and Evrysdi costs and a Part B/Part D routing split that changes patient cost by drug.
NPHC's annual Pompe ERT budget runs SAR 100-160M across 80-120 patients, at SAR 800K-1.2M for alglucosidase versus SAR 1.2-1.8M for avalglucosidase. A new entrant should target SAR 2.0-2.5M a year, with switch approvals clearing at only 40-60%.
An estimated 500,000+ US patients aged 70+ have undiagnosed ATTRwt-CM, against only 70,000-100,000 currently diagnosed and treated. A separate 100,000+ Val122Ile hereditary carrier pool sits alongside it.
GCC gMG has no single price. Efgartigimod costs SAR 300,000-600,000/yr through private VHI, a different figure through hospital pharmacy committees, and a third through NPHC exceptional access, with a unified formulary price still 12-18 months out.
Lanadelumab lists near $450,000 a year against berotralstat's roughly $95,000, and ICER's 2021 fair-value benchmark for berotralstat lands almost exactly on that list price. The three 2025 entrants carry no ICER anchor of their own.
Near-universal newborn screening puts the UK's 15,000-17,000 SCD patients on the registry with confidence, but only the 4,000-6,000 hydroxycarbamide-inadequate subset is the addressable population for a new non-gene agent.
National Amyloidosis Centre-anchored epidemiology puts UK ATTRwt-CM prevalence at 20,000-40,000. Only 3,000-4,000 patients are on NICE-commissioned tafamidis today, leaving 15,000-36,000 undiagnosed.
US Pompe prevalence runs 5,000 to 10,000 patients, 70-80% late-onset. Of the roughly 2,000 LOPD patients on enzyme replacement therapy, 375 to 600 are inadequate responders, the addressable population any new agent must reach.
NICE rejected Zolgensma in 2021 on cost per QALY, then reversed in 2023 through its Long-Term Value Framework. That framework, not the PAS discount, is the real UK SMA pricing lever, and it sets an estimated £1.2-1.6M net cost against a £4.5-7.5M lifetime chronic-therapy alternative.